Dipyridamole and headache

Future Neurology

Volumn 2, Issue 3, 2007, Pages 279-283

  Diener, Hans Christoph ^a   Davidai, Giora ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Aspirin; Dipyridamole; Headache; Stroke prevention

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; CLOPIDOGREL; DIPYRIDAMOLE; DIPYRONE; NITRIC OXIDE DONOR; PARACETAMOL; PLACEBO; SILDENAFIL;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG WITHDRAWAL; EUROPE; HIGH RISK PATIENT; HUMAN; LOW DRUG DOSE; MIGRAINE; MIGRAINE WITH AURA; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SINGLE DRUG DOSE; SUSTAINED RELEASE FORMULATION; SYSTEMATIC REVIEW;

EID: 34249312992     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.2.3.279     Document Type: Review

References (12)

1. Diener HC, Cuhna L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996).
2. The ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet 367, 1665-1673 (2006).
3. Diener HC, Forbes C, Riekkinen PJ et al.: European Stroke Prevention Study 2: Efficacy and safety data. J. Neurol. Sci. 151(Suppl.) S1-S77 (1997).
4. De Schreyver E, on behalf of the European/Australian Stroke Prevention in Reversible Ischemia Trial (ESPRIT) Group: Design of ESPRIT: an international ramdomized trial for secondary prevention of non-disabling cerebral ischemia of arterial origin. Cerebrovasc. Dis. 10, 147-150 (2000).
5. The ESPS Group: The European Stroke Prevention Study (ESPS). Principal endpoints. Lancet 2(8572), 1351-1354 (1987).
6. Theis JGW, Deichsel G, Marshall S: Rapid development of tolernace to dipyridamole-associated headaches. Br. J. Clin. Pharmacol. 48, 750-755 (1999).
7. Kruuse C, Jacobsen TB, Lassen LH et al.: Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J. Cereb. Blood Flow Metab. 20(9), 1372-1379 (2000).
8. Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J: Dipyridamole may induce migraine in patients with migraine without aura. Cephalalgia 26(8), 925-933 (2006).
9. Lindgren A, Husted S, Staaf G, Ziegler B: Dipyridamole and headache - a pilot study of initial dose titration. J. Neurol. Sci. 223(2), 179-184 (2004).
10. Chang YJ, Ryu SJ, Lee TH: Dose titration to reduce dipyridamole-related headache. Cerebrovasc. Dis. 22(4), 258-262 (2006).
11. Lipton RB, Bigal ME, Kolodner KB et al.: Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology 63(6), 1099-1101 (2004).
12. Diener HC, Sacco R, Yusuf S, for the Steering Committee and PRoFESS Study Group: Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens and telmisartan vs. placebo in patients with strokes: the Prevention Regimen For Effectively Avoiding Second Strokes (PRoFESS) trial. J. Neurol. 23, 368-380 (2007).